Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
Related news for (VAXX)
- Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
- Vaxxinity Issues Shareholder Letter
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
- Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
- Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates